Remix Therapeutics Reports First Patient Dosing in Two of REM-422’s P-I Studies for Treating ACC and AML or High-Risk MDS
Shots:
- Remix has recruited and dosed the first patient in two P-I dose escalation & expansion trials assessing the safety, PK/PD & anti-tumor activity of REM-422 to treat recurrent or metastatic adenoid cystic carcinoma (ACC) in one and r/r acute myeloid leukemia/high-risk myelodysplastic syndromes (AML or high-risk MDS) in the other study
- The US FDA also granted orphan drug designation to the company’s REM-422 for treating ACC and AML
- REM-422 (oral) is a potent and selective small molecule that reduces MYB mRNA & subsequent protein expression. It triggers nonsense-mediated decay (NMD) of the transcript by incorporating poison exons into the mRNA transcript
Ref: Remix Therapeutics | Image: Remix Therapeutics
Related News:- Blue Arbor’s RESTORE Neuromuscular Interface System Receives FDA Breakthrough Device Designation & TAP Enrolment
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
